Literature DB >> 22682143

Splanchnic vein thrombosis: new risk factors and management.

Marco P Donadini1, Francesco Dentali, Walter Ageno.   

Abstract

Splanchnic vein thrombosis (SVT) is a rather heterogeneous disease which involve one or more abdominal veins draining from different organs, including small and large bowel, liver, spleen and pancreas, and it may be associated with a wide spectrum of underlying disorders, either local or systemic. The role of new risk factors for SVT, including the JAK2 V617F mutation and the paroxysmal nocturnal hemoglobinuria clone, has been highlighted in recent years. The clinical presentations of SVT are variable and, not uncommonly, may include the concomitant presence of extensive thrombosis and gastrointestinal bleeding, thus representing a clinical challenge for treatment decisions. High quality evidence on the acute and long-term management is substantially lacking, thus requiring further research on SVT.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682143     DOI: 10.1016/S0049-3848(12)70025-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria.

Authors:  Marc Sorigue; Jordi Juncà; Elisa Orna; Nevena Romanic; Edurne Sarrate; Jordi Castellvi; Montse Soler; Ines Rodríguez-Hernandez; Evarist Feliu; Susana Ruiz
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

3.  JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis?

Authors:  Pratibha Dhiman; Priyanka Saxena
Journal:  Case Rep Hematol       Date:  2015-03-24

4.  Splanchnic vein thrombosis following renal transplantation: a case report.

Authors:  Erhan Tatar; Adam Uslu; Ahmet Aykas; Funda Tasli; Ozgur Oztekin; Gulsum Akgun Cagliyan
Journal:  BMC Nephrol       Date:  2013-07-22       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.